<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172819</url>
  </required_header>
  <id_info>
    <org_study_id>EPOC1505</org_study_id>
    <nct_id>NCT03172819</nct_id>
  </id_info>
  <brief_title>Special Combination of OBP-301 and Pembrolizumab</brief_title>
  <official_title>An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toshihiko Doi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncolys BioPharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center Hospital East</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and
      safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1a part:

      To evaluate safety and tolerability in combination of OBP-301 and Pembrolizumab in patient
      with advanced or metastatic solid tumor and to determine recommended dose in phase 1b part.

      Phase 1b part:

      To evaluate safety and potential efficacy in combination of OBP-301 and Pembrolizumab in
      patients in expanded arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>4weeks</time_frame>
    <description>Dose limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>3 years</time_frame>
    <description>Response rate by RECIST ver. 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>3 years</time_frame>
    <description>Rate of adverse event</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers:Efficacy evaluations according to immune status</measure>
    <time_frame>3 years</time_frame>
    <description>Immune status will be analyzed using biopsy and blood samples by flow cytometry, RNA seq, whole exome sequencing, and immunohistochemistry, etc.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>OBP-301+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OBP-301+Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OBP-301</intervention_name>
    <description>Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.</description>
    <arm_group_label>OBP-301+Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.</description>
    <arm_group_label>OBP-301+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Be willing and able to provide written informed consent/assent for the trial.

          2. Be &gt;=18 years of age on the day of signing the informed consent.

          3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          4. Have histologically or cytologically confirmed advanced or metastatic solid tumor with
             possibility of intratumoral injection, for which no effective standard therapy exists
             or standard therapy has failed.

          5. Have one or more evaluable lesions based on RECIST 1.1

             *Evaluable lesions: measurable lesion and/or non-measurable lesion

          6. Be willing to provide tissue; newly obtained endoscopic biopsy specimens or
             formalin-fixed, paraffin-embedded (FFPE) block specimens.

          7. Female subjects of childbearing potential have a negative urine or serum pregnancy
             test within 7 days prior to enrollment. If the urine test is positive or cannot be
             confirmed as negative, a serum pregnancy test will be required. It is allowed that the
             test at the same day at 7 days prior to enrollment. And male / female subjects of
             childbearing potential must be agree to use an adequate method of contraception
             starting with signing the informed consent through 120 days after the last dose of
             study medication.

          8. Demonstrated adequate organ function as defined in following criteria. All screening
             labs should be performed within 7 days of enrollment. It is allowed that the labs at
             the same day at 7days prior to enrollment.

        Note: Subject must not have taken transfusion, hematopoietic agent; granulocyte-colony
        stimulating factor (G-CSF) etc., and/or oxygen inhalation within 7 days before the
        screening labs.

          1. Absolute neutrophil count (ANC)&gt;=1,500 /mm3

          2. Platelets&gt;=100,000 /mm3

          3. Hemoglobin&gt;=9.0 g/dL

          4. Serum total bilirubin&lt;=2.0 mg/dL

          5. aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT)&lt;=100
             IU/L for subjects with liver metastases&lt;=200 IU/L

          6. Serum creatinine&lt;= 1.5 mg/dL; or if serum creatinine &gt; 1.5 mg/dL, creatinine/clearance
             &gt;=60 mL/min (Cockcroft-Gault formula)

        Exclusion criteria

          1. Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy within 4 weeks of study Day 1.

          2. Has an active autoimmune disease that has required systemic treatment in past 2 years.

          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to study Day 1.

          4. Has known active central nervous system metastases and/or carcinomatous meningitis.

          5. Has had prior anti-cancer monoclonal antibody chemotherapy, targeted small molecule
             therapy, or radiation therapy within 2 weeks prior to study Day 1 or immunotherapy
             targeted to Programmed cell death 1 (PD-1), PD-L1, PD-L2 within 4 weeks prior to Da y
             1 or OBP-301 study, who has not recovered from adverse events due to a previously
             administered agent.

          6. Has a known additional malignancy that is progressing or requires active treatment.

          7. Has received a live vaccine within 30 days of planned start of study therapy.

          8. Has a known history of Human Immunodeficiency Virus.

          9. Has known active Hepatitis B or Hepatitis C.

         10. Has known history of, or any evidence of active, non-infectious pneumonitis.

         11. Has an active infection requiring systemic therapy.

         12. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         13. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment.

         14. Previous severe hypersensitivity to another monoclonal antibody

         15. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshihiko Doi, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Center Hospital East</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takashi Kojima, Dr</last_name>
    <phone>+81-4-7133-1111</phone>
    <phone_ext>91266</phone_ext>
    <email>OBPem_core@east.ncc.go.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takashi Kojima, Dr</last_name>
      <phone>+81-4-7133-1111</phone>
      <phone_ext>91266</phone_ext>
      <email>OBPem_core@east.ncc.go.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center Hospital East</investigator_affiliation>
    <investigator_full_name>Toshihiko Doi</investigator_full_name>
    <investigator_title>Chief / Division of experimental therapeutics</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

